A lot of interesting tidbits in the transcript .
Amazing improvement in accuracy
Dexcom has been able to achieve an outstanding MARD of 9% (fingersticks=5.6%) via an improved G4 algorithm. This improved algorithm may get get pushed out to current G4 users but I'm guessing this will be a G5 thing. With improved accuracy, Dexcom really believes they can someday achieve FDA approval as a finger-stick replacement and this in turn will leverage future coverage of CGM under medicare.
They hope to submit their G5 to the FDA by year end. The G5 will beam readings via bluetooth and initially it will work with the iPhone. The mobile app faces the full Class III regulatory pathway but not the device that would run it, i.e. the iPhone, other smartphones, even a smart watch will not require FDA approvals. Very cool, this means that within the next 2-3 years most if not all smartphones will be able to display CGM as soon as Dexcom develops the mobile app for all of the smartphone OS. I'm guessing Android will be next to follow iPhone, and then Windows (Blackberry works with Android apps).
They made some encouraging comments about increasing coverage of sensors as pharmacy versus DME. This could be a game-changer for folks like me for whom cost is knocking Dexcom out of the picture. "...we are moving rapidly. And so, there's -- a good number of patients are getting processed that way. And contracts are falling into line the way we want them to...any patient that comes in here, we ping -- we call it ping, we ping their pharmacy benefit first. If we can get them product through the pharmacy at a lower co-pay, we run with it."
Dexcom rocks! They keep working to improve their product and it never ends.